COVID-19

Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis |
Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post COVID-19 Syndrome After SARS-CoV-2 Vaccination versus Influenza Vaccination |
Neurological Post-COVID Syndrome is Associated with Substantial Impairment of Verbal Short-term and Working Memory

Mpox Vaccination Hesitancy, Previous Immunization Coverage, and Vaccination Readiness in the African Region | Global Prevalence and Correlates of Mpox Vaccine Acceptance and Uptake |
The Effect of Nirmatrelvir/ritonavir on Short- and Long-term Adverse Outcomes from COVID-19 |
Epidemiological Insights into Chronic Urticaria, Vitiligo, Alopecia Areata, and Herpes Zoster following COVID-19 Infection | Impact of Extended-course Oral Nirmatrelvir/ritonavir in Established Long COVID

In-hospital Outcomes of Healthcare-associated Coronavirus Disease 2019 (Omicron) Versus Healthcare-associated Influenza: A Retrospective, Nationwide Cohort Study in Switzerland | Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74, 41 SARS-CoV-2–Positive Patients: A Nationwide Cohort Study from the Czech Republic

The Burden of All-Cause Mortality Following Influenza-Associated Hospitalizations | Initial Effectiveness of mRNA-1273 against SARS-CoV-2 Infection | 2024 Update of the RECOVER-Adult Long COVID Research Index | Real-world Effectiveness and Causal Mediation Study of BNT162b2 |
Personality and Neuropsychiatric Symptoms in Individuals Diagnosed with Long COVID | Post-COVID Condition Risk Factors and Symptom Clusters

BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age | Post-acute Sequelae of COVID-19 in Cancer Patients: Two Cohorts in UK and Hong Kong

Trial Stops Enrollment after Tpoxx Fails to Speed Clade 2 Mpox Healing or Pain Relief | Relative Effectiveness of Homologous NVX-CoV2373 and BNT162b2 COVID-19 Vaccinations in South Korea

Estimated Effectiveness of Influenza Vaccines | Benefit of Early Oseltamivir Therapy for Adults | Maternal Infection of SARS-CoV-2 | The Effect of Pre-COVID and Post-COVID Vaccination |
Delayed Induction of Noninflammatory SARS-CoV-2 Spike-Specific IgG4 Antibodies | Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations |
Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission |
Transcutaneous Electrical Nerve Stimulation for Fibromyalgia-like Syndrome | Mitigating the Risks of Post-acute Sequelae of SARS-CoV-2 Infection | Measurement of Circulating Viral Antigens Post-SARS-CoV-2 Infection

Association between Use of a Voluntary Isolation Centre and Reduced Household SARS-CoV-2 Transmission |
Risks of SARS-CoV-2 JN.1 Infection and COVID-19–Associated Emergency Department Visits | Real Clinical Effectiveness of Molnupiravir against 30-day Mortality | Time to Sustained Recovery Among Outpatients With COVID-19 | Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 | Remdesivir for 5 or 10 Days in Patients | Remdesivir for Treatment of COVID-19 | Neurologic Manifestations of Long COVID Disproportionately Affect Young and Middle-age Adults

Serological Evidence of Mpox Virus Infection During Peak Mpox Transmission in New York City, July to August 2022 | N95 Filtering Facepiece Respirator Reuse, Extended Use, and Filtration Efficiency | Enhanced Placental Antibody Transfer Efficiency with Longer Interval Between Maternal RSV Vaccination and Birth

Real-world Effectiveness of Nirmatrelvir-Ritonavir and Molnupiravir in Non-hospitalised Adults with Covid-19: A Population-based, Retrospective Cohort Study (sic) Cohort Study | Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated with Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial |
Post-acute Sequelae of SARS-CoV-2 Cardiovascular Symptoms are Associated with Trace-level Cytokines that Affect Cardiomyocyte Function